Literature DB >> 12496431

Chimeras of labile toxin one and cholera toxin retain mucosal adjuvanticity and direct Th cell subsets via their B subunit.

Prosper N Boyaka1, Mari Ohmura, Kohtaro Fujihashi, Toshiya Koga, Masafumi Yamamoto, Mi-Na Kweon, Yoshifumi Takeda, Raymond J Jackson, Hiroshi Kiyono, Yoshikazu Yuki, Jerry R McGhee.   

Abstract

Native cholera toxin (nCT) and the heat-labile toxin 1 (nLT) of enterotoxigenic Escherichia coli are AB5-type enterotoxins. Both nCT and nLT are effective adjuvants that promote mucosal and systemic immunity to protein Ags given by either oral or nasal routes. Previous studies have shown that nCT as mucosal adjuvant requires IL-4 and induces CD4-positive (CD4+) Th2-type responses, while nLT up-regulates Th1 cell production of IFN-gamma and IL-4-independent Th2-type responses. To address the relative importance of the A or B subunits in CD4+ Th cell subset responses, chimeras of CT-A/LT-B and LT-A/CT-B were constructed. Mice nasally immunized with CT-A/LT-B or LT-A/CT-B and the weak immunogen OVA developed OVA-specific, plasma IgG Abs titers similar to those induced by either nCT or nLT. Both CT-A/LT-B and LT-A/CT-B promoted secretory IgA anti-OVA Ab, which established their retention of mucosal adjuvant activity. The CT-A/LT-B chimera, like nLT, induced OVA-specific mucosal and peripheral CD4+ T cells secreting IFN-gamma and IL-4-independent Th2-type responses, with plasma IgG2a anti-OVA Abs. Further, LT-A/CT-B, like nCT, promoted plasma IgG1 more than IgG2a and IgE Abs with OVA-specific CD4+ Th2 cells secreting high levels of IL-4, but not IFN-gamma. The LT-A/CT-B chimera and nCT, but not the CT-A/LT-B chimera or nLT, suppressed IL-12R expression and IFN-gamma production by activated T cells. Our results show that the B subunits of enterotoxin adjuvants regulate IL-12R expression and subsequent Th cell subset responses.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12496431     DOI: 10.4049/jimmunol.170.1.454

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  16 in total

1.  Transcutaneous immunization induces mucosal CTLs and protective immunity by migration of primed skin dendritic cells.

Authors:  Igor M Belyakov; Scott A Hammond; Jeffrey D Ahlers; Gregory M Glenn; Jay A Berzofsky
Journal:  J Clin Invest       Date:  2004-04       Impact factor: 14.808

2.  Interleukin-1 family cytokines as mucosal vaccine adjuvants for induction of protective immunity against influenza virus.

Authors:  Hiroyuki Kayamuro; Yasuo Yoshioka; Yasuhiro Abe; Shuhei Arita; Kazufumi Katayama; Tetsuya Nomura; Tomoaki Yoshikawa; Ritsuko Kubota-Koketsu; Kazuyoshi Ikuta; Shigefumi Okamoto; Yasuko Mori; Jun Kunisawa; Hiroshi Kiyono; Norio Itoh; Kazuya Nagano; Haruhiko Kamada; Yasuo Tsutsumi; Shin-ichi Tsunoda
Journal:  J Virol       Date:  2010-09-29       Impact factor: 5.103

Review 3.  Inducing Mucosal IgA: A Challenge for Vaccine Adjuvants and Delivery Systems.

Authors:  Prosper N Boyaka
Journal:  J Immunol       Date:  2017-07-01       Impact factor: 5.422

4.  Mucosal adjuvant properties of the Shigella invasin complex.

Authors:  Robert W Kaminski; K Ross Turbyfill; Edwin V Oaks
Journal:  Infect Immun       Date:  2006-05       Impact factor: 3.441

5.  A bacterial flagellin, Vibrio vulnificus FlaB, has a strong mucosal adjuvant activity to induce protective immunity.

Authors:  Shee Eun Lee; Soo Young Kim; Byung Chul Jeong; Young Ran Kim; Soo Jang Bae; Ouk Seon Ahn; Je-Jung Lee; Ho-Chun Song; Jung Mogg Kim; Hyon E Choy; Sun Sik Chung; Mi-Na Kweon; Joon Haeng Rhee
Journal:  Infect Immun       Date:  2006-01       Impact factor: 3.441

Review 6.  Structure, biological functions and applications of the AB5 toxins.

Authors:  Travis Beddoe; Adrienne W Paton; Jérôme Le Nours; Jamie Rossjohn; James C Paton
Journal:  Trends Biochem Sci       Date:  2010-03-02       Impact factor: 13.807

7.  Sublingual targeting of STING with 3'3'-cGAMP promotes systemic and mucosal immunity against anthrax toxins.

Authors:  Tara L Martin; Junbae Jee; Eunsoo Kim; Haley E Steiner; Estelle Cormet-Boyaka; Prosper N Boyaka
Journal:  Vaccine       Date:  2017-03-24       Impact factor: 3.641

8.  Immunogenicity of a Staphylococcus aureus-cholera toxin A2/B vaccine for bovine mastitis.

Authors:  N Misra; T F Wines; C L Knopp; R Hermann; L Bond; B Mitchell; M A McGuire; J K Tinker
Journal:  Vaccine       Date:  2018-05-05       Impact factor: 3.641

9.  A Vibrio cholerae ghost-based subunit vaccine induces cross-protective chlamydial immunity that is enhanced by CTA2B, the nontoxic derivative of cholera toxin.

Authors:  Eno E Ekong; Daniel N Okenu; Jayanti Mania-Pramanik; Qing He; Joseph U Igietseme; Godwin A Ananaba; Deborah Lyn; Carolyn Black; Francis O Eko
Journal:  FEMS Immunol Med Microbiol       Date:  2008-11-18

10.  Nasal vaccination with the 40-kilodalton outer membrane protein of Porphyromonas gingivalis and a nontoxic chimeric enterotoxin adjuvant induces long-term protective immunity with reduced levels of immunoglobulin E antibodies.

Authors:  Fumiki Momoi; Tomomi Hashizume; Tomoko Kurita-Ochiai; Yoshikazu Yuki; Hiroshi Kiyono; Masafumi Yamamoto
Journal:  Infect Immun       Date:  2008-04-14       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.